Efficacy and Safety of Dapagliflozin in Acute Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT04298229

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04298229
Other papers using this trial's data
  • Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure Journal of the American College of Cardiology, 2024-04-09 DOI, PubMed 38569758
  • Interaction of Kidney Function and Dapagliflozin in Patients With Acute Heart Failure: A Pre-Specified Analysis of DICTATE-AHF The American journal of cardiology, 2026-07-01 DOI, PubMed 42013970

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04298229. Randomized; single masking; primary purpose treatment. Start 2020-04-01 (actual); primary completion 2023-05-17 (actual). Results posted on 2024-03-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
Acronym
DICTATE-AHF
Condition
Heart Failure
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapagliflozin 10 MG
Intervention (Other)
Protocolized Diuretic Therapy
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04298229
Content hash
15f413446f29fc6b9364dbf0783be46aa550ca1bf504d5c2340d5fbca57fe7ae